United Therapeutics (UTHR) said Tuesday that a phase 3 study evaluating the use of nebulized Tyvaso to treat idiopathic pulmonary fibrosis, of IPF, has reached full enrollment.
The 598-patient Teton 1 study is part of three-study clinical trial program assessing the use of inhaled treprostinil in IPF and a similar condition of progressive pulmonary fibrosis, the biotechnology company said.
Enrollment for the Teton 2 trial, which is evaluating the use of Tyvaso in IPF in patients outside the US and Canada was completed in July last year, with top-line data expected in the second half of this year, it said.
If both studies are successful, United Therapeutics said the data will be used to support a filing for the US Food and Drug Administration's approval to add IPF to the labeled indications for nebulized Tyvaso.
Price: 351.22, Change: -3.36, Percent Change: -0.95
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.